Aspirin in the Prevention of Cardiovascular Events in Hemodialysis Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2010 by Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Taipei Veterans General Hospital, Taiwan
Information provided by:
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
ClinicalTrials.gov Identifier:
NCT01198379
First received: August 24, 2010
Last updated: September 23, 2010
Last verified: February 2010
  Purpose

The study is prospectively initiated to: (1) evaluate the alterations in platelet function to aspirin therapy and the prevalence of aspirin resistance in patients with chronic kidney disease undergoing hemodialysis, and (2) compare the incidence of vascular events (myocardial infarction, cardiac death, stroke, vascular access thrombosis, or revascularization procedure) and the safety profile among placebo-treated, aspirin-resistant and aspirin-sensitive patients.


Condition Intervention Phase
End-Stage Renal Disease
Drug: aspirin
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Treatment
Official Title: Efficacy of Monitoring of Aspirin Responsiveness in the Prevention of Cardiovascular Events and Decrease in Bleeding Complications in Patients With End-Stage Kidney Disease Undergoing Hemodialysis

Resource links provided by NLM:


Further study details as provided by Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation:

Primary Outcome Measures:
  • the prevalence of aspirin resistance [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • the incidence of vascular events (myocardial infarction, cardiac death, stroke, vascular access thrombosis, or revascularization procedure) [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 250
Study Start Date: February 2010
Estimated Study Completion Date: February 2013
Estimated Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Aspirin Drug: aspirin
aspirin 100 mg qd for 3 years
Placebo Comparator: Sugar pills
Hemodialysis (HD) patients receive placebo not containing aspirin in this study.
Drug: Placebo

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with end-stage renal disease who are undergoing long-term hemodialysis.

Exclusion Criteria:

Patients will be excluded if there is evidence of

  • a recent history of acute uremia,
  • previous adverse reaction to a aspirin or history of aspirin hypersensitivity (eg, aspirin-induced asthma or angioedema),
  • concurrent treatment with other antiplatelet agent (clopidogrel or ticlopidine), steroidal drugs, or nonsteroidal anti-inflammatory drugs,
  • high immediate risk for bleeding (eg, active peptic ulceration, recent injury, or hemophilia), or
  • life-threatening condition other than end-stage renal disease or vascular disease (eg, non-skin cancer).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01198379

Contacts
Contact: Ying-Hwa Chen, MD, PhD yhchen@vghtpe.gov.tw

Locations
Taiwan
Taipei Veterans General Hospital Recruiting
Taipei, Taiwan
Contact: Ying-Hwa Chen, MD, PhD       yhchen@vghtpe.gov.tw   
Sponsors and Collaborators
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Taipei Veterans General Hospital, Taiwan
Investigators
Study Director: Der-Cherng Tarng, MD, PhD Taipei Veterans General Hospital, Taiwan
  More Information

No publications provided

Responsible Party: Ying-Hwa Chen, Taipei Veterans General Hospital
ClinicalTrials.gov Identifier: NCT01198379     History of Changes
Other Study ID Numbers: BTCGHTN01
Study First Received: August 24, 2010
Last Updated: September 23, 2010
Health Authority: Taiwan: Institutional Review Board

Keywords provided by Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation:
aspirin
aspirin resistance
hemodialysis
cardiovascular
Prevalence of aspirin resistance, cardiovascular events, and safety profile

Additional relevant MeSH terms:
Kidney Diseases
Kidney Failure, Chronic
Urologic Diseases
Renal Insufficiency, Chronic
Renal Insufficiency
Aspirin
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents
Hematologic Agents
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics
Central Nervous System Agents

ClinicalTrials.gov processed this record on September 22, 2014